Biometrics Matters Ltd, Hamilton 2003-05-12 Room I1.09, University of Waikato I give an overview of the modern, highly-regulated drug development process from compound formulation through to post-market Phase IV. I then concentrate on statistical aspects of trials occurring in Phases I to III as it is clinical development which I am most familiar with from my work in the UK pharmaceutical industry. |